HIV-1 therapeutic vaccines.
In this review, we address recent advances in the understanding of the pathogenesis of human immunodeficiency type 1 virus infection, which have provided the rationale for present trials of therapeutic vaccines. We shall relate this work to lessons of the past few years both in the use of highly active antiretroviral therapy to attempt eradication of the HIV virus, and in the study of treatment interruptions.
Kinloch-de Loes
S
S
Department of HIV/Thoracic Medicine, Department of Medicine, The Royal Free Centre for HIV Medicine, Royal Free Campus, Royal Free and University College Medical School, London, NW3 2PF, UK. sabine@kinloch.u-net.com
Autran
B
B
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002908:Chronic Disease; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000276:immunology / Q000472:pathogenicity; D006801:Humans
D016915:AIDS Vaccines; D019380:Anti-HIV Agents